Within-trial resource utilization and costs of patients randomized to treatment with imatinib (STI571) versus interferon-alpha (IFN-alpha) combined with cytarabine (Ara-C) in newly diagnosed patients with chronic myeloid leukemia in chronic phase.
Publication
, Conference
Reed, SD; Radeva, JI; Glendenning, A; Schulman, KA
Published in: BLOOD
November 16, 2002
Duke Scholars
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2002
Volume
100
Issue
11
Start / End Page
187A / 187A
Location
PHILADELPHIA, PENNSYLVANIA
Publisher
AMER SOC HEMATOLOGY
Conference Name
44th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Reed, S. D., Radeva, J. I., Glendenning, A., & Schulman, K. A. (2002). Within-trial resource utilization and costs of patients randomized to treatment with imatinib (STI571) versus interferon-alpha (IFN-alpha) combined with cytarabine (Ara-C) in newly diagnosed patients with chronic myeloid leukemia in chronic phase. In BLOOD (Vol. 100, pp. 187A-187A). PHILADELPHIA, PENNSYLVANIA: AMER SOC HEMATOLOGY.
Reed, S. D., J. I. Radeva, A. Glendenning, and K. A. Schulman. “Within-trial resource utilization and costs of patients randomized to treatment with imatinib (STI571) versus interferon-alpha (IFN-alpha) combined with cytarabine (Ara-C) in newly diagnosed patients with chronic myeloid leukemia in chronic phase.” In BLOOD, 100:187A-187A. AMER SOC HEMATOLOGY, 2002.
Reed SD, Radeva JI, Glendenning A, Schulman KA. Within-trial resource utilization and costs of patients randomized to treatment with imatinib (STI571) versus interferon-alpha (IFN-alpha) combined with cytarabine (Ara-C) in newly diagnosed patients with chronic myeloid leukemia in chronic phase. In: BLOOD. AMER SOC HEMATOLOGY; 2002. p. 187A-187A.
Reed, S. D., et al. “Within-trial resource utilization and costs of patients randomized to treatment with imatinib (STI571) versus interferon-alpha (IFN-alpha) combined with cytarabine (Ara-C) in newly diagnosed patients with chronic myeloid leukemia in chronic phase.” BLOOD, vol. 100, no. 11, AMER SOC HEMATOLOGY, 2002, pp. 187A-187A.
Reed SD, Radeva JI, Glendenning A, Schulman KA. Within-trial resource utilization and costs of patients randomized to treatment with imatinib (STI571) versus interferon-alpha (IFN-alpha) combined with cytarabine (Ara-C) in newly diagnosed patients with chronic myeloid leukemia in chronic phase. BLOOD. AMER SOC HEMATOLOGY; 2002. p. 187A-187A.
Published In
BLOOD
ISSN
0006-4971
Publication Date
November 16, 2002
Volume
100
Issue
11
Start / End Page
187A / 187A
Location
PHILADELPHIA, PENNSYLVANIA
Publisher
AMER SOC HEMATOLOGY
Conference Name
44th Annual Meeting of the American-Society-of-Hematology
Related Subject Headings
- Immunology
- 3213 Paediatrics
- 3201 Cardiovascular medicine and haematology
- 3101 Biochemistry and cell biology
- 1114 Paediatrics and Reproductive Medicine
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology